1. PRRX1 is a master transcription factor of stromal fibroblasts for myofibroblastic lineage progression
- Author
-
Keun-Woo Lee, So-Young Yeo, Jeong-Ryeol Gong, Ok-Jae Koo, Insuk Sohn, Woo Yong Lee, Hee Cheol Kim, Seong Hyeon Yun, Yong Beom Cho, Mi-Ae Choi, Sugyun An, Juhee Kim, Chang Ohk Sung, Kwang-Hyun Cho, and Seok-Hyung Kim
- Subjects
Mice ,Multidisciplinary ,Cancer-Associated Fibroblasts ,Neoplasms ,Animals ,General Physics and Astronomy ,General Chemistry ,Fibroblasts ,Myofibroblasts ,General Biochemistry, Genetics and Molecular Biology ,Transcription Factors - Abstract
Although stromal fibroblasts play a critical role in cancer progression, their identities remain unclear as they exhibit high heterogeneity and plasticity. Here, a master transcription factor (mTF) constructing core-regulatory circuitry, PRRX1, which determines the fibroblast lineage with a myofibroblastic phenotype, is identified for the fibroblast subgroup. PRRX1 orchestrates the functional drift of fibroblasts into myofibroblastic phenotype via TGF-β signaling by remodeling a super-enhancer landscape. Such reprogrammed fibroblasts have myofibroblastic functions resulting in markedly enhanced tumorigenicity and aggressiveness of cancer. PRRX1 expression in cancer-associated fibroblast (CAF) has an unfavorable prognosis in multiple cancer types. Fibroblast-specific PRRX1 depletion induces long-term and sustained complete remission of chemotherapy-resistant cancer in genetically engineered mice models. This study reveals CAF subpopulations based on super-enhancer profiles including PRRX1. Therefore, mTFs, including PRRX1, provide another opportunity for establishing a hierarchical classification system of fibroblasts and cancer treatment by targeting fibroblasts.
- Published
- 2022
- Full Text
- View/download PDF